Management of Skin Lesions in Patients with Epidermolysis Bullosa by Topical Treatment: Systematic Review and Meta-Analysis
-
Published:2024-01-19
Issue:2
Volume:12
Page:261
-
ISSN:2227-9032
-
Container-title:Healthcare
-
language:en
-
Short-container-title:Healthcare
Author:
Pabón-Carrasco Manuel1ORCID, Caceres-Matos Rocio2ORCID, Roche-Campos Marta3, Hurtado-Guapo Maria Antonia4ORCID, Ortiz-Romero Mercedes5, Gordillo-Fernández Luis M.5, Pabón-Carrasco Daniel6, Castro-Méndez Aurora5ORCID
Affiliation:
1. Research Group PAIDI-CTS-1054: “Interventions and Health Care, Red Cross (ICSCRE)”, Nursing Department, Faculty of Nursing, Physiotherapy and Podiatry, University of Seville, 6 Avenzoar ST, 41009 Seville, Spain 2. Research Group PAIDI-CTS-1050: “Complex Care, Chronicity and Health Outcomes”, Nursing Department, Faculty of Nursing, Physiotherapy and Podiatry, University of Seville, 6 Avenzoar ST, 41009 Seville, Spain 3. Hospital Universitario de Cruce, 48903 Bilbao, Spain 4. Nursing Department, Faculty of Nursing, Extremadura University, 06006 Badajoz, Spain 5. Faculty of Nursing, Physiotherapy and Podiatry, University of Seville, 41009 Seville, Spain 6. Crux Roxa Rehabilitación, 41008 Sevilla, Spain
Abstract
Epidermolysis bullosa (EB) is the overarching term for a set of rare inherited skin fragility disorders that result from mutations in at least 20 different genes. Currently, there is no cure for any of the EB subtypes associated with various mutations. Existing therapies primarily focus on alleviating pain and promoting early wound healing to prevent potential complications. Consequently, there is an urgent need for innovative therapeutic approaches. The objective of this research was to assess the efficacy of various topical treatments in patients with EB with the goal of achieving wound healing. A secondary objective was to analyse the efficacy of topical treatments for symptom reduction. A literature search was conducted using scientific databases, including The Cochrane Library, Medline (Pubmed), Web of Science, CINHAL, Embase, and Scopus. The protocol review was registered in PROSPERO (ID: 418790), and inclusion and exclusion criteria were applied, resulting in the selection of 23 articles. Enhanced healing times were observed compared with the control group. No conclusive data have been observed on pain management, infection, pruritus episodes, and cure rates over time. Additionally, evidence indicates significant progress in gene therapies (B-VEC), as well as cell and protein therapies. The dressing group, Oleogel S-10, allantoin and diacerein 1%, were the most represented, followed by fibroblast utilisation. In addition, emerging treatments that improve the patient’s innate immunity, such as calcipotriol, are gaining attention. However, more trials are needed to reduce the prevalence of blistering and improve the quality of life of individuals with epidermolysis bullosa.
Subject
Health Information Management,Health Informatics,Health Policy,Leadership and Management
Reference82 articles.
1. Epidermolysis bullosa;Bardhan;Nat. Rev. Dis. Primer,2020 2. Epidermolysis bullosa: Advances in research and treatment;Prodinger;Exp. Dermatol.,2019 3. Epidermolysis Bullosa: A Review of the Tissue-Engineered Skin Substitutes Used to Treat Wounds;Hunt;Mol. Diagn. Ther.,2022 4. Baquero-Fernández, C., Herrera-Ceballos, E., López-Gutiérrez, J.C., De Lucas-Laguna, R., Romero-Gómez, J., Serrano-Martínez, M.C., and Torrelo, F. (2023, June 10). Guía de Atención Clínica Integral de la Epidermólisis Bullosa Hereditaria. Ministerio de Sanidad y Consumo. Available online: https://www.sanidad.gob.es/profesionales/prestacionesSanitarias/publicaciones/docs/epidermolisisBullosa.pdf. 5. Birch Bark Extract: A Review in Epidermolysis Bullosa;Heo;Drugs,2023
|
|